Ambit Biosciences Inc., of San Diego, presented data for quizartinib, including results from a Phase IIb study showing that a clinical response rate of 47 percent in subjects with FLT3-ITD-positive relapsed acute myeloid leukemia (AML) receiving lower doses – 30 mg – of drug.